RxDoctor Payments Data

Lauren Riddle, MD

Family Medicine · Waco, TXNPI 1710368105

Payments from drug & device makers

$1,494in general payments, 2019–2025

Across 65 payments — averaging $22.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$271
  • Phathom Pharmaceuticals, Inc.$244
  • AbbVie$173
  • Pfizer$173
  • Dexcom, Inc.$150
  • Amgen$106
  • plus $376 from 15 others

What the payments were for

  • Food & beverage$1,494100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,494 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$36,989
Medicare patients
89
Services billed
408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$44,778
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$21,836
MounjaroTirzepatide20$21,315
Nurtec OdtRimegepant Sulfate11$21,092
EliquisApixaban13$10,257
FarxigaDapagliflozin Propanediol12$6,714
BelsomraSuvorexant12$5,367
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$2,286
Fluticasone Propionate HfaFluticasone Propionate12$2,142
Omeprazole126$1,845
Pregabalin65$1,766
Dexlansoprazole DrDexlansoprazole11$1,488
Atorvastatin Calcium197$1,399
Aripiprazole55$1,376
Gabapentin89$1,084

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$271$44,77847 claims
PfizerNurtec Odt, Eliquis$173$31,35024 claims
Lilly USA, LLCMounjaro$16$21,31520 claims
AstraZenecaFarxiga$47$6,71412 claims
MerckBelsomra$32$5,36712 claims
AbbVieSynthroid$173$1,01715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Waco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →